Supply Montelukast Sodium Raw Materials powder Montelukast Sodium

CAS:151767-02-1

MF:C35H37ClNNaO3S

MW:610.18

EINECS:604-813-7

Specification: 99% min Montelukast Sodium

Sample:Montelukast Sodium powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Montelukast Sodium of Usage and Synthesis.

Montelukast sodium generally plays a role in the prevention and long-term treatment of asthma in adults and children, and can also play a role in the treatment of aspirin-sensitive asthma, and can also be used to prevent bronchoconstriction caused by exercise.

Montelumast sodium is an organic compound, belonging to the medical insurance class A drug, the drug can usually be taken with food or other time periods, but to be taken for a long time, regardless of patients with renal dysfunction, elderly patients, deterioration stage or control stage, moderate and severe liver damage patients, generally will not adjust the dose, usage and dosage, it is recommended to consult the doctor in detail.

Eat a light diet during the medication and avoid eating spicy food to avoid adverse drug reactions.

Uses of Montelukast Sodium.

Montelukast sodium is a selective cysteylleukotriene receptor antagonist.

This tablet is indicated for the prevention and long-term treatment of asthma in adults 15 years of age and older, including the prevention of daytime and nighttime asthma symptoms and the treatment of aspirin

In patients with sensitive asthma, as well as prevention of exercise-induced bronchoconstriction, it can also reduce symptoms caused by allergic rhinitis, including seasonal allergies

Rhinitis and perennial allergic rhinitis.

Pharmacological action of Montelukast Sodium.

Montelukast is a selective leukotriene receptor antagonist approved for oral treatment of asthma and allergic rhinitis. It is also a potent oral formulation that can significantly improve indicators of pro-inflammation. Biochemical and pharmacological bioassays have shown that Montelukast sodium has a high affinity and selectivity for CysLT1 receptors (compared to other airway receptors of pharmacological importance such as prostaglandins, cholinergics, and beta-adrenergic receptors). Montelukast efficiently inhibits the physiological effects of LTC4, LTD4, and LTE4 binding to the CysLT1 receptor without any receptor activation. A second type of cysteinylleukotriene receptor (CysLT2) exists in the lungs, but may be limited to blood vessels. To date, neither receptor has been cloned, so the situation of CysLT receptor is mainly explained by receptor binding assay and pharmacological analysis. It is now believed that Montelukast sodium does not antagonize the CysLT2 receptor.

Product method of Bulk Montelukast Sodium Powder.